RMP
IRD

Richards, Merrill & Peterson’s Opus Genetics IRD Stock Holding History

Richards, Merrill & Peterson’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-70
Closed -$83 – 534
2024
Q4 		$83 Buy
+70
New +$80 ﹤0.01% 500

Other funds holding IRD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Richards, Merrill & Peterson's IRD Position: Q1 2025 in Review

Richards, Merrill & Peterson sold out of Opus Genetics (IRD) in Q1 2025, closing a stake of 70 shares — an estimated $83 sold.

Richards, Merrill & Peterson first reported a position in IRD in Q4 2024 and held it in 1 quarter. The position peaked at $83 in Q4 2024. 46 funds tracked by Wall St. Rank hold IRD as of Q1 2025.

  • Richards, Merrill & Peterson reported no remaining Opus Genetics position as of Q1 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 70 Opus Genetics shares in Q1 2025, an estimated $83.
  • Richards, Merrill & Peterson first reported a position in Opus Genetics in Q4 2024 and held it in 1 quarter.
  • Richards, Merrill & Peterson's Opus Genetics position peaked at $83 in Q4 2024.
  • 46 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q1 2025, filed 7 May 2025.